MicroRNA-455-3p as a potential peripheral biomarker for Alzheimer's disease

被引:136
作者
Kumar, Subodh [1 ]
Vijayan, Murali [1 ]
Reddy, P. Hemachandra [1 ,2 ,3 ,4 ,5 ,6 ]
机构
[1] Texas Tech Univ, Hlth Sci Ctr, Grad Sch Biomed Sci, Biomarker Unit,Garrison Inst Aging, Lubbock, TX 79430 USA
[2] Texas Tech Univ, Hlth Sci Ctr, Grad Sch Biomed Sci, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA
[3] Texas Tech Univ, Hlth Sci Ctr, Grad Sch Biomed Sci, Dept Pharmacol & Neurosci, Lubbock, TX 79430 USA
[4] Texas Tech Univ, Hlth Sci Ctr, Grad Sch Biomed Sci, Dept Neurol, Lubbock, TX 79430 USA
[5] Texas Tech Univ, Hlth Sci Ctr, Grad Sch Biomed Sci, Dept Speech Language & Hearing Sci, Lubbock, TX 79430 USA
[6] Texas Tech Univ, Hlth Sci Ctr, Grad Sch Biomed Sci, Dept Publ Hlth, Lubbock, TX 79430 USA
关键词
AMYLOID-BETA; EXPRESSION; DIAGNOSIS; PLASMA; MIRNA; RISK;
D O I
10.1093/hmg/ddx267
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The purpose of our study was to identify microRNAs (miRNAs) as early detectable peripheral biomarkers in Alzheimer's disease (AD). To achieve our objective, we assessed miRNAs in serum samples from AD patients and Mild cognitive impairment (MCI) subjects relative to healthy controls. We used Affymetrix microarray analysis and validated differentially expressed miRNAs using qRT-PCR. We further validated miRNA data using AD postmortem brains, amyloid precursor protein transgenic mice and AD cell lines. We identified a gradual upregulation of four miRNAs: miR-455-3p, miR-4668-5p, miR-36133p and miR-4674. A fifth miRNA, mir-6722, was down-regulated in persons with AD and mild cognitive impairment compared with controls. Validation analysis by qRT-PCR showed significant upregulation of only miR-455-3p (P = 0.007) and miR-46685p (P = 0.016) in AD patients compared with healthy controls. Furthermore, qRT-PCR analysis of the AD postmortem brains with different Braak stages also showed upregulation of miR-455-3p (P = 0.016). However, receiver operating characteristic curves (ROC) curve analysis revealed a significant area under curve (AUC) value only for miR-455-3p in the serum (AUROC = 0.79; P = 0.015) and brains (AUROC = 0.86; P = 0.016) of AD patients. Expression analysis of amyloid precursor protein transgenic mice also revealed high level of mmu-miR-455-3p (P = 0.004) in the cerebral cortex (AD-affected) region of brain and low in the non-affected area, i.e. cerebellum. Furthermore, human and mouse neuroblastoma cells treated with the amyloid- b(1-42) peptide also showed a similarly higher expression of miR-455-3p. Functional analysis of differentially expressed miRNAs via the miR-path indicated that miR-455-3p was associated in the regulation of several biological pathways. Genes associated with these pathways were found to have a crucial role in AD pathogenesis. An increase in miR-455-3p expression found in AD patients and Ab pathologies unveiled its biomarker characteristics and a precise role in AD pathogenesis.
引用
收藏
页码:3808 / 3822
页数:15
相关论文
共 50 条
  • [31] MGAT3 mRNA: A Biomarker for Prognosis and Therapy of Alzheimer's Disease by Vitamin D and Curcuminoids
    Fiala, Milan
    Mahanian, Michelle
    Rosenthal, Mark
    Mizwicki, Matthew T.
    Tse, Eric
    Cho, Tiffany
    Sayre, James
    Weitzman, Rachel
    Porter, Verna
    JOURNAL OF ALZHEIMERS DISEASE, 2011, 25 (01) : 135 - 144
  • [32] Dysregulation and Diagnostic Potential of microRNA in Alzheimer's Disease
    Pan, Yaoqian
    Liu, Ruizhu
    Terpstra, Erin
    Wang, Yanqing
    Qiao, Fangfang
    Wang, Jin
    Tong, Yigang
    Pan, Bo
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 49 (01) : 1 - 12
  • [33] Potential Roles of α-amylase in Alzheimer's Disease: Biomarker and Drug Target
    Chen, Win Ning
    Tang, Kim San
    Yeong, Keng Yoon
    CURRENT NEUROPHARMACOLOGY, 2022, 20 (08) : 1554 - 1563
  • [34] Perivascular spaces as a potential biomarker of Alzheimer's disease
    Lynch, Miranda
    Pham, William
    Sinclair, Benjamin
    O'Brien, Terence J.
    Law, Meng
    Vivash, Lucy
    FRONTIERS IN NEUROSCIENCE, 2022, 16
  • [35] The biomarker and therapeutic potential of miRNA in Alzheimer's disease
    Bekris, Lynn M.
    Leverenz, James B.
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2015, 5 (01) : 61 - 74
  • [36] The Potential of Neurofilament Light as a Biomarker in Alzheimer's Disease
    Xiong, Yong-lan
    Meng, Tao
    Luo, Jing
    Zhang, Hua
    EUROPEAN NEUROLOGY, 2021, 84 (01) : 6 - 15
  • [37] Circulating miRNAs as Potential Biomarkers in Alzheimer's Disease
    Galimberti, Daniela
    Villa, Chiara
    Fenoglio, Chiara
    Serpente, Maria
    Ghezzi, Laura
    Cioffi, Sara M. G.
    Arighi, Andrea
    Fumagalli, Giorgio
    Scarpini, Elio
    JOURNAL OF ALZHEIMERS DISEASE, 2014, 42 (04) : 1261 - 1267
  • [38] Syndecan-3 as a Novel Biomarker in Alzheimer's Disease
    Hudak, Anett
    Letoha, Annamaria
    Vizler, Csaba
    Letoha, Tamas
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (06)
  • [39] MicroRNA Landscape in Alzheimer's Disease
    Cogoni, Carlo
    Ruberti, Francesca
    Barbato, Christian
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2015, 14 (02) : 168 - 175
  • [40] Plasma Myeloperoxidase as a Potential Biomarker of Patient Response to Anti-Dementia Treatment in Alzheimer's Disease
    Wright, Joy R.
    Deen, Quazi Fahm E.
    Stevenson, Anna
    Telford-Cooke, Leolie L.
    Parker, Craig
    Martin-Ruiz, Carmen
    Steinert, Joern R.
    Kalaria, Raj N.
    Mukaetova-Ladinska, Elizabeta B.
    JOURNAL OF ALZHEIMERS DISEASE, 2022, 89 (04) : 1483 - 1492